^
BIOMARKER:
MET exon 14 mutation
i
Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Entrez ID:
MET exon 14 mutation
NSCLC
tepotinib
Sensitive
:
A1
MET exon 14 mutation
NSCLC
capmatinib
Sensitive
:
A1
MET exon 14 mutation
NSCLC
crizotinib
Sensitive
:
A2
MET exon 14 mutation
LUAD
tepotinib
Sensitive
:
C1
MET exon 14 mutation
NSCLC
HMPL-504
Sensitive
:
C2
MET exon 14 mutation
NSCLC
APL-101
Sensitive
:
C2
MET exon 14 mutation
NSCLC
Immunotherapy
Sensitive
:
C3
MET exon 14 mutation
NSCLC
c-MET inhibitor
Sensitive
:
C3
MET exon 14 mutation
NSCLC
nivolumab
Sensitive
:
C3
MET exon 14 mutation
Biliary Tract Cancer
c-MET inhibitor
Sensitive
:
C3
MET exon 14 mutation
NSCLC
c-MET inhibitor + Tyrosine kinase inhibitor
Resistant
:
C3
MET exon 14 mutation
NSCLC
pembrolizumab
Sensitive
:
C4
MET exon 14 mutation
LUAD
crizotinib
Sensitive
:
C4
MET exon 14 mutation
LUAD
cabozantinib tablet
Sensitive
:
C4
MET exon 14 mutation
Gastric Cancer
Sym015
Sensitive
:
D
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our